“Front Line Treatment of DLBCL - Time for Individualized Therapy”

Friday, April 21, 2017

Walker Auditorium

12:30 p.m. – 1:30 p.m.

Lunch available on a first come, first served basis

Presented by:

Dr. Greg Nowakowski

Hematology

Supervisor of Hematology Advanced

Associate Consultant

Mayo Clinic Rochester

Learning Objectives:

Upon conclusion of this program, participants should be able to:

• Discuss outcomes of patients with DLBCL
• Recognize how molecular profiling drives therapy of DLBCL
• Discuss progress in methods of DLBCL subtyping – clinic ready vs. research assays
• Recognize selected activity of novel agents in molecular subtypes of DLBCL

  “Speaker, Doctor Greg Nowakowski, has noted financial relationship with Celgene, Abbvie, Roche, Morphosys, Phamacyclics. He intends to discuss off-label/ investigational use of a commercial product device. Course Director, Doctor James Foran, has no financial relationships to disclose or intentions to discuss off-label/ investigational use of a commercial product device.”

  Mayo Clinic College of Medicine and Science is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

  Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  Please direct all inquiries for non-physician CEU’s to Clinical Education at (3-0326)

  For further information, contact Jen Gatchell 3-2795